Parasitism

DrTalks Announces the Silent Killers Summit for Chronic Inflammatory Diseases Taking Place from February 20 - 26, 2024

Retrieved on: 
Thursday, November 30, 2023

CARLSBAD, Calif., Nov. 30, 2023 /PRNewswire/ -- DrTalks has recently announced the Silent Killers - Reversing the Root Cause of Chronic Inflammatory Disease Summit. It's a virtual event that aims to help individuals uncover the root causes of their health challenges, taking place from February 20 to 26, 2024. Hosted by Laura Frontiero, FNP-BC, CCD, this event equips attendees with the knowledge and tools essential for overcoming lethal diseases by addressing their underlying causes.

Key Points: 
  • This online event delves deep into the heart of chronic inflammatory diseases, exploring often overlooked causes such as parasites and toxins.
  • The Silent Killers Summit is free for all attendees and is taking place from February 20 - 26, 2024.
  • CARLSBAD, Calif., Nov. 30, 2023 /PRNewswire/ -- DrTalks has recently announced the Silent Killers - Reversing the Root Cause of Chronic Inflammatory Disease Summit .
  • It's a virtual event that aims to help individuals uncover the root causes of their health challenges, taking place from February 20 to 26, 2024.

af&co. & Carbonate To Debut The "Sweet 16" Edition Of Their Annual Hospitality Trends Report

Retrieved on: 
Monday, November 13, 2023

SAN FRANCISCO, Nov. 13, 2023 /PRNewswire-PRWeb/ -- af&co., one of the country's top boutique lifestyle/hospitality marketing and public relations firms, and Carbonate, a boutique creative services and brand communications agency, are thrilled to celebrate a "Sweet 16" years of trend forecasting with the release of their 16th annual Hospitality Trends Report. The report presents a comprehensive overview of the trends and practices that will shape the hospitality industry in 2024 by identifying key influences in food, beverage, hotels & travel, design, marketing, and social media.

Key Points: 
  • & Carbonate hospitality trends report forecasts the biggest influences in food, beverage, hotels, and more that will shape the industry in 2024.
  • The report presents a comprehensive overview of the trends and practices that will shape the hospitality industry in 2024 by identifying key influences in food, beverage, hotels & travel, design, marketing, and social media.
  • "The expectations have never been higher for restaurant and hospitality brands, and people are craving new experiences and connection.
  • The af&co./Carbonate trends report has become an anticipated industry resource for hospitality professionals, providing actionable insights to help brands increase relevance and attract business.

Beyond2020 Improves Access to Clean Water for 10,000 Rural Malaysians

Retrieved on: 
Thursday, November 9, 2023

Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses

Key Points: 
  • Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses
    ABU DHABI, UAE, Nov. 9, 2023 /PRNewswire/ -- Beyond2020, the UAE-driven humanitarian initiative, has installed water filters in 25 communities in the Sabah and Sarawak regions of Malaysia, providing clean drinking water to 10,000 people.
  • This deployment contributes significantly to Malaysia's ongoing efforts to enhance access to reliable, clean water.
  • The UAE's Beyond2020 initiative, which has delivered safe drinking water to 10,000 Malaysians, showcases how innovative solutions can tackle our water challenges, particularly in the rural areas.
  • Water interventions are necessary to ensure that vulnerable populations, particularly children, women and the elderly, have access to clean drinking water.

Beyond2020 Improves Access to Clean Water for 10,000 Rural Malaysians

Retrieved on: 
Thursday, November 9, 2023

Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses

Key Points: 
  • Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses
    ABU DHABI, UAE, Nov. 9, 2023 /PRNewswire/ -- Beyond2020, the UAE-driven humanitarian initiative, has installed water filters in 25 communities in the Sabah and Sarawak regions of Malaysia, providing clean drinking water to 10,000 people.
  • This deployment contributes significantly to Malaysia's ongoing efforts to enhance access to reliable, clean water.
  • The UAE's Beyond2020 initiative, which has delivered safe drinking water to 10,000 Malaysians, showcases how innovative solutions can tackle our water challenges, particularly in the rural areas.
  • Water interventions are necessary to ensure that vulnerable populations, particularly children, women and the elderly, have access to clean drinking water.

Beyond2020 Improves Access to Clean Water for 10,000 Rural Malaysians

Retrieved on: 
Thursday, November 9, 2023

Beyond2020, the UAE-driven humanitarian initiative, has installed water filters in 25 communities in the Sabah and Sarawak regions of Malaysia, providing clean drinking water to 10,000 people.

Key Points: 
  • Beyond2020, the UAE-driven humanitarian initiative, has installed water filters in 25 communities in the Sabah and Sarawak regions of Malaysia, providing clean drinking water to 10,000 people.
  • This deployment contributes significantly to Malaysia's ongoing efforts to enhance access to reliable, clean water.
  • The UAE's Beyond2020 initiative, which has delivered safe drinking water to 10,000 Malaysians, showcases how innovative solutions can tackle our water challenges, particularly in the rural areas.
  • Water interventions are necessary to ensure that vulnerable populations, particularly children, women and the elderly, have access to clean drinking water.

Un rapport d’experts détaille les problèmes scientifiques et réglementaires posés par les procédés génétiques de lutte antiparasitaire

Retrieved on: 
Wednesday, November 8, 2023

Comme on connaît mal l’efficacité et les effets potentiels de la lutte génétique contre les parasites, sa réglementation doit être suffisamment souple pour tenir compte de l’incertitude persistante et protéger contre les menaces.

Key Points: 
  • Comme on connaît mal l’efficacité et les effets potentiels de la lutte génétique contre les parasites, sa réglementation doit être suffisamment souple pour tenir compte de l’incertitude persistante et protéger contre les menaces.
  • « L’évaluation de l’utilité, de l’innocuité et de l’adéquation de la lutte génétique contre les parasites nécessite d’importants investissements en recherche et développement, ainsi qu’un dialogue continu avec la population.
  • »
    L’Agence de réglementation de la lutte antiparasitaire de Santé Canada a demandé au CAC d’évaluer les défis scientifiques, bioéthiques et réglementaires de l’utilisation d’organismes à génome modifié et de procédés génétiques dans la lutte antiparasitaire.
  • Cerner les défis et les possibilités pour le Canada dresse un aperçu de l’usage possible des procédés génétiques de lutte antiparasitaire et explique comment les risques qu’ils comportent peuvent influencer leur développement, leur introduction et leur surveillance responsables.

Laboratory Testing and PCR Technology Lead the India Infectious Disease Diagnostics Market, Transforming Disease Detection and Management - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023

The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.

Key Points: 
  • The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.
  • The India emerging infectious disease diagnostics market is currently in an emerging phase.
  • The India emerging infectious disease diagnostics market plays a pivotal role in modern biotechnology, clinical diagnostics, and pathogen research.
  • The India emerging infectious disease diagnostics market is segmented into key categories:
    In FY2022, laboratory testing was the dominant application segment in the India emerging infectious disease diagnostics market.

IDEXX Expands SNAP Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-borne Diseases

Retrieved on: 
Wednesday, November 8, 2023

WESTBROOK, Maine, Nov. 8, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the upcoming launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases, including canine leishmaniosis. The SNAP Leish 4Dx Test uses the trusted SNAP 4Dx Plus testing platform, which detects Lyme disease, heartworm disease, ehrlichiosis, and anaplasmosis. By replacing Lyme disease detection with detection of leishmaniosis, a more prevalent endemic disease in certain regions of the world, the SNAP Leish 4Dx Test supports vector-borne disease diagnosis globally. The test will be available in Europe and Asia beginning February 2024.

Key Points: 
  • WESTBROOK, Maine, Nov. 8, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the upcoming launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases, including canine leishmaniosis.
  • The SNAP Leish 4Dx Test uses the trusted SNAP 4Dx Plus testing platform, which detects Lyme disease, heartworm disease, ehrlichiosis, and anaplasmosis.
  • By replacing Lyme disease detection with detection of leishmaniosis, a more prevalent endemic disease in certain regions of the world, the SNAP Leish 4Dx Test supports vector-borne disease diagnosis globally.
  • "Parasites and vector-borne diseases like leishmaniosis are an increasing risk to the health of pets globally," said Jay Mazelsky, IDEXX President and Chief Executive Officer.

PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)

Retrieved on: 
Thursday, November 2, 2023

This marks an important step in PaxMedica's efforts to explore potential monetization of a Priority Review Voucher (PRV) prior to filing the NDA for PAX-101 for the treatment of African Sleeping Sickness.

Key Points: 
  • This marks an important step in PaxMedica's efforts to explore potential monetization of a Priority Review Voucher (PRV) prior to filing the NDA for PAX-101 for the treatment of African Sleeping Sickness.
  • The engagement with Bourne Partners underscores PaxMedica's commitment to optimizing its valuable assets to support the development of innovative healthcare solutions.
  • Leveraging Bourne Partners' extensive experience and network within the healthcare sector, PaxMedica aims to enhance its initiatives in the field of neurologic disorders and expedite critical research and development efforts.
  • "We are excited to engage Bourne Partners to explore the structures that could potentially allow the company to monetize the value of a potential PRV," stated Howard Weisman, Chairman and CEO of PaxMedica.

Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit

Retrieved on: 
Tuesday, October 31, 2023

SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, announced that in a presentation given today at the 7th Annual Dermatology Drug Development Summit titled “Finding the New Ground Between Safety & Efficacy in Drug Development,” Recludix’s senior vice president of biology, Paul Smith, Ph.D., reviewed the challenges associated with inhibition of the JAK/STAT pathway through TYK2 and JAK inhibitors and presented preclinical data with Recludix’s STAT3 inhibitor REX-7117, which potently and selectively targets the STAT3 Src Homology 2 (SH2) domain. The presentation is available on the company’s website under the section titled “Events.”

Key Points: 
  • “Importantly, other approaches to inhibiting the JAK/STAT pathway by targeting TYK2 or JAK have resulted in undesirable safety consequences, such as increased risk of infections or altered hematopoiesis.
  • It provides durable STAT3 inhibition and maintains in vivo selectivity against other STAT proteins, even after the administration of multi-day oral dosing in a preclinical model.
  • In a translational Th17 preclinical model of psoriasis, once daily REX-7117 (300 mg/kg) was superior to a clinically-relevant dose of deucravacitinib (1 mg/kg).
  • Moreover, twice daily REX-7117 (300 mg/kg) was comparable to deucravacitinib at a supra-clinical dose (30 mg/kg), reinforcing the rationale of STAT3 targeting as a potential disease-modifying opportunity.